🇺🇸 FDA
Pipeline program

Dasiglucagon 4 mg/ml

ZP4207-17106

Phase 3 small_molecule active

Quick answer

Dasiglucagon 4 mg/ml for Children with congenital hyperinsulinism is a Phase 3 program (small_molecule) at Zealand Pharma A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Zealand Pharma A/S
Indication
Children with congenital hyperinsulinism
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials